Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 765130, 5 pages
http://dx.doi.org/10.1155/2014/765130
Research Article

Comparison of Two Analytical Platforms for CSF Biomarkers of Alzheimer’s Disease

1Department of Neurology, University General Hospital of Alicante, Avenida Pintor Baeza 12, 8a C, 03010 Alicante, Spain
2Laboratory of Immunology, University General Hospital of Alicante, Avenida Pintor Baeza 12, 8a C, 03010 Alicante, Spain
3Preventive Medicine Service, University General Hospital of Alicante, Avenida Pintor Baeza 12, 8a C, 03010 Alicante, Spain

Received 10 February 2014; Revised 13 April 2014; Accepted 7 May 2014; Published 29 May 2014

Academic Editor: Hanna Rosenmann

Copyright © 2014 Jose Antonio Monge-Argilés et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Blennow and H. Hampel, “CSF markers for incipient Alzheimer's disease,” The Lancet Neurology, vol. 2, no. 10, pp. 605–613, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. H. L. Weiner and D. Frenkel, “Immunology and immunotherapy of Alzheimer's disease,” Nature Reviews Immunology, vol. 6, pp. 404–416, 2006. View at Publisher · View at Google Scholar
  3. T. S. M. Reijn, M. O. Rikkert, W. J. A. van Geel, D. de Jong, and M. M. Verbeek, “Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid β42 and tau proteins,” Clinical Chemistry, vol. 53, no. 5, pp. 859–865, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. G. M. McKhann, D. S. Knopman, H. Chertkow et al., “The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease,” Alzheimer's & Dementia, vol. 7, no. 3, pp. 263–269, 2011. View at Publisher · View at Google Scholar
  5. M. S. Albert, S. T. DeKosky, D. Dickson et al., “The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease,” Alzheimer's & Dementia, vol. 7, no. 3, pp. 270–279, 2011. View at Publisher · View at Google Scholar
  6. A. M. Fagan, L. M. Shaw, C. Xiong et al., “Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, Total tau, and P-tau181 for identifying Alzheimer disease amyloid plaque pathology,” Archives of Neurology, vol. 68, no. 9, pp. 1137–1144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Morales-Gonzalez, J. I. Gonzalez-Montalvo, T. del Ser Quijano, and F. Bermejo-Pareja, “Estudio de validación del S-IQCODE: la versión Española del iformant questionnaire on cognitive decline in the elderly,” Archivos de Neurobiología, vol. 55, pp. 262–266, 1992. View at Google Scholar
  8. A. Olsson, H. Vanderstichele, N. Andreasen et al., “Simultaneous measurement of β-amyloid(1-42), total Tau, and phosphorylated Tau (Thr181) in cerebrospinal fluid by the xMAP technology,” Clinical Chemistry, vol. 51, no. 2, pp. 336–345, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. L. S. Wang, Y. Y. Leung, S. K. Chang et al., “Comparison of xMAP and ELISA assays for detecting CSF biomarkers of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 31, pp. 439–445, 2012. View at Google Scholar
  10. D. J. Irwin, C. T. McMillan, J. B. Toledo et al., “Comparison of cerebrospinal fluid levels of tau and Aβ1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms,” Archives of Neurology, vol. 69, no. 8, pp. 1018–1025, 2012. View at Publisher · View at Google Scholar · View at Scopus